KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Non-Current Debt (2016 - 2025)

Astrazeneca (AZN) has 3 years of Non-Current Debt data on record, last reported at $24.7 billion in Q4 2025.

  • For Q4 2025, Non-Current Debt fell 6.76% year-over-year to $24.7 billion; the TTM value through Dec 2025 reached $24.7 billion, down 6.76%, while the annual FY2025 figure was $24.7 billion, 6.76% down from the prior year.
  • Non-Current Debt reached $24.7 billion in Q4 2025 per AZN's latest filing, down from $26.5 billion in the prior quarter.
  • Across five years, Non-Current Debt topped out at $26.5 billion in Q4 2024 and bottomed at $22.4 billion in Q4 2023.
  • Average Non-Current Debt over 3 years is $24.5 billion, with a median of $24.7 billion recorded in 2025.
  • Peak YoY movement for Non-Current Debt: increased 18.52% in 2024, then decreased 6.76% in 2025.
  • A 3-year view of Non-Current Debt shows it stood at $22.4 billion in 2023, then grew by 18.52% to $26.5 billion in 2024, then decreased by 6.76% to $24.7 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Debt were $24.7 billion in Q4 2025, $26.5 billion in Q4 2024, and $22.4 billion in Q4 2023.